Index -
P/E -
EPS (ttm) -6.16
Insider Own 5.96%
Shs Outstand 93.73M
Perf Week 5.63%
Market Cap 12.72B
Forward P/E 13.73
EPS next Y 9.80
Insider Trans 0.92%
Shs Float 88.87M
Perf Month 6.02%
Income -535.98M
PEG -
EPS next Q 0.04
Inst Own 85.66%
Short Float 5.48%
Perf Quarter 9.55%
Sales 1.24B
P/S 10.23
EPS this Y 153.04%
Inst Trans 6.40%
Short Ratio 5.71
Perf Half Y 99.92%
Book/sh 9.17
P/B 14.68
EPS next Y 218.64%
ROA -16.77%
Short Interest 4.87M
Perf Year 7.56%
Cash/sh 17.74
P/C 7.59
EPS next 5Y -
ROE -86.15%
52W Range 55.25 - 159.89
Perf YTD 39.55%
Dividend Est. -
P/FCF -
EPS past 5Y -1.21%
ROI -25.13%
52W High -15.84%
Beta 0.96
Dividend TTM -
Quick Ratio 3.45
Sales past 5Y 32.89%
Gross Margin 84.34%
52W Low 143.56%
ATR (14) 4.75
Dividend Ex-Date -
Current Ratio 3.95
EPS Y/Y TTM 24.04%
Oper. Margin -21.54%
RSI (14) 68.22
Volatility 4.28% 3.23%
Employees 1314
Debt/Eq 1.63
Sales Y/Y TTM 33.26%
Profit Margin -43.11%
Recom 1.48
Target Price 167.00
Option/Short Yes / Yes
LT Debt/Eq 1.48
EPS Q/Q 134.77%
Payout -
Rel Volume 2.81
Prev Close 130.90
Sales Surprise 8.94%
EPS Surprise 2768.22%
Sales Q/Q 53.54%
Earnings May 01 AMC
Avg Volume 853.58K
Price 134.57
SMA20 9.16%
SMA50 6.94%
SMA200 20.20%
Trades
Volume 1,354,670
Change 2.80%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-31-24 Initiated
BMO Capital Markets
Outperform
$170
Dec-13-23 Resumed
Citigroup
Buy
$113
Dec-12-23 Initiated
Deutsche Bank
Buy
$109
Nov-21-23 Initiated
Wedbush
Outperform
$224
Oct-31-23 Downgrade
Oppenheimer
Outperform → Perform
Oct-31-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
$166 → $40
Jun-23-23 Downgrade
Evercore ISI
Outperform → In-line
$139
Apr-26-23 Initiated
SMBC Nikko
Outperform
$185
Apr-04-23 Initiated
Citigroup
Buy
$179
Mar-01-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$141 → $187
Dec-22-22 Reiterated
BTIG Research
Buy
$125 → $160
Dec-16-22 Upgrade
UBS
Neutral → Buy
$100 → $158
Apr-04-22 Resumed
Cantor Fitzgerald
Overweight
$140
Jan-05-22 Reiterated
Needham
Buy
$157 → $150
Dec-09-21 Upgrade
Oppenheimer
Perform → Outperform
$125
Nov-05-21 Upgrade
JP Morgan
Neutral → Overweight
$130
Sep-15-21 Upgrade
Guggenheim
Neutral → Buy
Aug-05-21 Upgrade
JP Morgan
Underweight → Neutral
$92 → $87
Jun-15-21 Initiated
BTIG Research
Buy
$110
Apr-26-21 Resumed
Credit Suisse
Neutral
$72
Show Previous Ratings
Today 11:30AM
11:13AM
11:08AM
07:52AM
06:01AM
(Thomson Reuters StreetEvents)
03:32AM
Loading…
03:32AM
May-01-24 08:55PM
07:30PM
07:30PM
05:20PM
05:06PM
04:19PM
(Associated Press Finance)
04:05PM
09:15AM
Apr-30-24 06:38PM
09:28AM
Loading…
09:28AM
Apr-29-24 03:20PM
(Investor's Business Daily)
Apr-24-24 08:30AM
Apr-13-24 09:39PM
Apr-08-24 04:13PM
(Investor's Business Daily)
Apr-06-24 08:45AM
Apr-02-24 07:04AM
Mar-29-24 04:00PM
11:30AM
Mar-26-24 07:49AM
Mar-25-24 10:00AM
Mar-17-24 08:50AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
Mar-12-24 01:18AM
09:03AM
Loading…
Mar-11-24 09:03AM
Mar-06-24 11:54PM
Mar-04-24 09:47AM
08:30AM
Mar-02-24 12:05AM
Feb-29-24 06:16PM
12:35PM
10:52AM
09:00AM
12:00AM
Feb-28-24 06:00PM
04:23PM
(Associated Press Finance)
04:05PM
07:15AM
Feb-27-24 08:48AM
Feb-21-24 11:24AM
08:30AM
Feb-20-24 10:00AM
Feb-19-24 03:26AM
Feb-16-24 11:23AM
11:22AM
08:46AM
07:41AM
07:22AM
07:00AM
Feb-15-24 07:45AM
Feb-11-24 01:45AM
Jan-31-24 06:29PM
Jan-29-24 07:37AM
07:12AM
07:00AM
06:50AM
Jan-26-24 05:15AM
Jan-25-24 09:45AM
Jan-22-24 05:47PM
09:55AM
09:38AM
Jan-16-24 03:57PM
09:02AM
Jan-10-24 11:43AM
06:17AM
Jan-09-24 11:22AM
10:52AM
07:15AM
Jan-08-24 11:55AM
Jan-04-24 09:55AM
Jan-02-24 08:30AM
Dec-29-23 06:27PM
08:44AM
Dec-28-23 10:07AM
Dec-27-23 06:26PM
Dec-26-23 06:56PM
Dec-22-23 02:49PM
10:15AM
08:00AM
06:33AM
Dec-17-23 09:45AM
Dec-15-23 09:55AM
Dec-12-23 12:43PM
Dec-09-23 07:00AM
Dec-01-23 11:31AM
Nov-30-23 06:34PM
Nov-29-23 09:55AM
Nov-27-23 09:50AM
Nov-24-23 10:26AM
Nov-18-23 06:49AM
Nov-16-23 06:35AM
Nov-13-23 09:55AM
07:57AM
Nov-10-23 12:58AM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Boor Kathryn Jean Director Mar 11 '24 Sale 122.93 761 93,550 7,516 Mar 11 08:00 PM Wigzell Hans Lennart Rudolf Director Mar 08 '24 Option Exercise 13.90 15,000 208,500 37,840 Mar 11 08:02 PM Wigzell Hans Lennart Rudolf Director Mar 08 '24 Sale 123.25 15,000 1,848,795 22,840 Mar 11 08:02 PM Mayo Stephen Director Mar 05 '24 Sale 122.96 3,135 385,480 6,621 Mar 06 08:00 PM Arif Bilal Chief Tech Ops Officer Mar 01 '24 Sale 128.84 2,000 257,676 26,836 Mar 05 08:00 PM Brown Ryan Edward EVP, General Counsel Mar 01 '24 Sale 125.34 2,000 250,680 31,827 Mar 05 08:00 PM Estepan Ian Michael Chief Financial Officer Mar 01 '24 Sale 128.30 1,200 153,960 39,114 Mar 05 08:00 PM BEHRENS M KATHLEEN Director Nov 03 '23 Option Exercise 29.03 15,000 435,450 174,993 Nov 06 08:00 AM Barry Richard Director Nov 03 '23 Buy 78.81 50,000 3,940,500 140,000 Nov 06 08:00 AM INGRAM DOUGLAS S President & CEO Nov 03 '23 Buy 79.36 25,225 2,001,800 390,307 Nov 06 08:00 AM Chambers Michael Andrew Director Aug 14 '23 Buy 109.47 9,979 1,092,429 246,996 Aug 15 08:00 AM Chambers Michael Andrew Director Aug 11 '23 Buy 108.05 23,686 2,559,272 237,017 Aug 14 08:00 AM Chambers Michael Andrew Director Aug 10 '23 Buy 106.15 34,867 3,701,067 213,331 Aug 11 07:40 AM Wigzell Hans Lennart Rudolf Director Aug 04 '23 Option Exercise 29.03 15,000 435,450 35,994 Aug 08 08:00 PM Wigzell Hans Lennart Rudolf Director Aug 04 '23 Sale 106.72 15,000 1,600,800 20,994 Aug 08 08:00 PM
Index RUT
P/E -
EPS (ttm) -2.32
Insider Own 7.44%
Shs Outstand 42.24M
Perf Week 1.50%
Market Cap 953.44M
Forward P/E -
EPS next Y -0.47
Insider Trans 0.00%
Shs Float 40.01M
Perf Month 7.17%
Income -97.22M
PEG -
EPS next Q -0.46
Inst Own 32.63%
Short Float 32.10%
Perf Quarter -7.49%
Sales 0.00M
P/S -
EPS this Y 7.54%
Inst Trans 5.13%
Short Ratio 16.80
Perf Half Y 9.45%
Book/sh 3.25
P/B 6.78
EPS next Y 77.86%
ROA -50.31%
Short Interest 12.84M
Perf Year -0.56%
Cash/sh 2.80
P/C 7.87
EPS next 5Y -
ROE -53.27%
52W Range 12.32 - 32.10
Perf YTD -2.02%
Dividend Est. -
P/FCF -
EPS past 5Y -30.45%
ROI -70.72%
52W High -31.29%
Beta -0.44
Dividend TTM -
Quick Ratio 9.13
Sales past 5Y 0.00%
Gross Margin -
52W Low 79.01%
ATR (14) 1.17
Dividend Ex-Date Dec 13, 2012
Current Ratio 9.13
EPS Y/Y TTM -22.28%
Oper. Margin 0.00%
RSI (14) 52.19
Volatility 3.31% 7.08%
Employees 29
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 99.50
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -5.65%
Payout -
Rel Volume 1.03
Prev Close 22.14
Sales Surprise -
EPS Surprise 3.85%
Sales Q/Q -
Earnings Feb 28 BMO
Avg Volume 764.53K
Price 22.06
SMA20 0.31%
SMA50 2.99%
SMA200 3.51%
Trades
Volume 443,035
Change -0.38%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-16-22 Downgrade
B. Riley Securities
Buy → Neutral
$44
Jul-15-21 Downgrade
Cantor Fitzgerald
Overweight → Neutral
$100
Jul-07-21 Reiterated
Maxim Group
Buy
$80 → $190
Apr-27-21 Initiated
B. Riley Securities
Buy
$78
Feb-16-21 Reiterated
H.C. Wainwright
Buy
$20 → $66
Oct-23-20 Initiated
Cantor Fitzgerald
Overweight
$24
Sep-23-20 Upgrade
H.C. Wainwright
Neutral → Buy
$20
May-18-20 Downgrade
H.C. Wainwright
Buy → Neutral
May-15-20 Downgrade
Maxim Group
Buy → Hold
Jan-10-20 Reiterated
Maxim Group
Buy
$3 → $12
May-01-24 09:10AM
Apr-30-24 01:16PM
Apr-15-24 09:20AM
Mar-25-24 09:13AM
Mar-13-24 10:45AM
09:15AM
Loading…
Mar-04-24 09:15AM
Feb-28-24 09:14AM
Feb-23-24 11:30AM
Feb-08-24 10:39AM
Feb-07-24 09:08AM
Feb-05-24 02:35PM
Jan-05-24 11:46AM
09:12AM
Dec-26-23 05:06AM
Dec-15-23 06:06PM
11:10AM
Loading…
Dec-13-23 11:10AM
(Investor's Business Daily)
Dec-12-23 02:02PM
09:13AM
Dec-08-23 07:31PM
Dec-07-23 04:01PM
Nov-14-23 09:53PM
Nov-07-23 09:39AM
09:01AM
Nov-06-23 09:15AM
Oct-31-23 08:15AM
Oct-25-23 09:15AM
Oct-19-23 09:59AM
Oct-16-23 07:01PM
05:26PM
Oct-13-23 03:29PM
(The Wall Street Journal) -15.28%
03:29PM
Loading…
03:29PM
(The Wall Street Journal)
12:45PM
11:21AM
Oct-12-23 11:43PM
Oct-06-23 03:13PM
Oct-05-23 09:15AM
Oct-02-23 09:00AM
Sep-18-23 09:15AM
Sep-14-23 06:30AM
Sep-13-23 05:20PM
Sep-11-23 09:10AM
Sep-06-23 09:15AM
Aug-29-23 07:30AM
Aug-03-23 09:07AM
Jul-29-23 11:30AM
Jul-13-23 07:31AM
Jul-05-23 11:44AM
09:15AM
Jun-27-23 09:15AM
Jun-12-23 10:19AM
09:15AM
Jun-01-23 09:15AM
May-30-23 12:06PM
May-23-23 09:50AM
May-12-23 04:39PM
May-11-23 02:40PM
(Investor's Business Daily)
09:15AM
May-08-23 09:15AM
May-01-23 09:00AM
Apr-26-23 09:12AM
Mar-09-23 09:45AM
Mar-04-23 07:20AM
Mar-03-23 07:07AM
(Thomson Reuters StreetEvents)
Feb-28-23 09:15AM
Feb-24-23 01:29PM
Feb-08-23 09:15AM
Feb-01-23 08:55AM
Jan-25-23 08:27PM
Jan-24-23 04:06PM
(Investor's Business Daily) -19.21%
12:22PM
09:15AM
Jan-18-23 10:35AM
(Investor's Business Daily)
Jan-12-23 09:40AM
Jan-03-23 09:16AM
Dec-20-22 09:15AM
Dec-06-22 09:15AM
Nov-22-22 12:30PM
Nov-18-22 01:30PM
Nov-16-22 10:43AM
Nov-15-22 10:00AM
Nov-14-22 03:54PM
(Yahoo Finance Video) +9.44%
Nov-07-22 09:00AM
06:15AM
Nov-04-22 10:49AM
Nov-03-22 09:15AM
Nov-01-22 02:21PM
Oct-31-22 05:50PM
06:15AM
Oct-27-22 09:15AM
Oct-25-22 05:50PM
Oct-17-22 05:50PM
Oct-13-22 09:15AM
Oct-11-22 06:00PM
06:00AM
Oct-05-22 06:15AM
Sep-30-22 10:35AM
Sep-29-22 06:15PM
Sep-27-22 01:11PM
Sep-23-22 04:11PM
(Investor's Business Daily) -18.00%
01:43PM
(Investor's Business Daily)
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROBERTSON SANFORD Director Apr 26 '24 Option Exercise 22.00 69,000 1,518,000 955,851 Apr 30 09:13 AM Barry Richard Director Apr 23 '24 Option Exercise 22.00 176,085 3,873,870 469,562 Apr 25 09:15 AM Kupiec James William Chief Medical Officer Apr 18 '24 Option Exercise 22.00 1,500 33,000 4,000 Apr 22 09:19 AM Schoen Eric Chief Financial Officer Apr 17 '24 Option Exercise 22.00 1,500 33,000 21,300 Apr 17 04:21 PM ROBERTSON SANFORD Director Aug 23 '23 Buy 17.45 30,000 523,500 886,851 Aug 24 04:06 PM Barry Richard Director Aug 22 '23 Buy 16.65 16,571 275,907 293,477 Aug 23 04:58 PM Barry Richard Director Aug 21 '23 Buy 16.80 1,906 32,021 276,906 Aug 23 04:58 PM SCANNON PATRICK J MD PHD Director Jun 12 '23 Option Exercise 0.95 1,000 950 1,000 Jun 12 04:53 PM BARBIER REMI President and CEO May 24 '23 Option Exercise 16.87 71,428 1,204,990 782,002 May 25 05:11 PM BARBIER REMI President and CEO May 24 '23 Option Exercise 16.87 14,285 240,988 390,397 May 25 05:11 PM ROBERTSON SANFORD Director May 10 '23 Option Exercise 17.79 9,284 165,170 856,851 May 10 04:08 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite